A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis

Overview of attention for article published in Frontiers in immunology, January 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (70th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter: 9 X users

Readers on

mendeley: 20 Mendeley

Summary X

So far, Altmetric has seen 12 X posts from 9 X users, with an upper bound of 49,136 followers.

A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis - Front Immunol https://t.co/P7ORiW1qL6

10 Feb 2022

Reply Repost Favourite

RT @UCAMIraras: 🪘 A todos los pacientes se les debe prescribir inmunosupresores orales. A Personalized Rituximab Retreatment Approach Based…

02 Feb 2022

Reply Repost Favourite

🪘 A todos los pacientes se les debe prescribir inmunosupresores orales. A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis https://t.co/W4NEMh86U9

02 Feb 2022

Reply Repost Favourite

RT @Yuz6Yusof: 📢Our📰is out. We proposed #rituximab retreatment pathway in ANCA #vasculitis 💠concomitant DMARDs 💠partial BVAS 6mo response->…

17 Jan 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 8 additional X posts.